Claims for Patent: 8,778,302

Summary for Patent: 8,778,302

Title:	Procaspase 8-mediated disease targeting
Abstract:	The invention provides compositions and method for delivering a therapeutic or diagnostic agent to a disease site in a mammal, the method comprising administering to the mammal a therapeutically or diagnostically effective amount of a pharmaceutical composition, wherein the pharmaceutical composition comprises the therapeutic or diagnostic agent coupled to a Procaspase 8 polypeptide and a pharmaceutically acceptable carrier.
Inventor(s):	Tai; Isabella (Vancouver, CA)
Assignee:	The University of British Columbia (Vancouver, BC, CA)
Application Number:	12/530,504
Patent Claims:	1. A pharmaceutical composition, the composition comprising a therapeutic or diagnostic agent coupled to a Procaspase 8 polypeptide and a pharmaceutically acceptable carrier, wherein the therapeutic or diagnostic agent is for the treatment or diagnosis of a cancer, and wherein the Procaspase 8 polypeptide comprises an amino acid sequence of any one of SEQ ID NOS: 1-18, 25, and 26. 2. The pharmaceutical composition of claim 1, wherein the diagnostic agent is selected from the group consisting of radioactive agents, MRI contrast agents, X-ray contrast agents, ultrasound contrast agents, and PET contrast agents. 3. The pharmaceutical composition of claim 1, wherein the therapeutic agent is selected from the group consisting of docetaxel, paclitaxel, taxanes, platinum compounds, antifolates, antimetabolites, antimitotics, DNA damaging agents, proapoptotics, differentiation inducing agents, antiangiogenic agents, antibiotics, hormones, peptides, antibodies, tyrosine kinase inhibitors, kinase inhibitors, anti-vascular endothelial growth factor compounds (anti-VEGFs), anti-epidermal growth factor receptor compounds (anti-EGFRs), tTF, TNF, radionuclides, and combinations thereof. 4. The pharmaceutical composition of claim 1, wherein the therapeutic agent is selected from the group consisting of genistein, adriamycin, ansamycin, asparaginase, bleomycin, busulphan, cisplatin, carboplatin, carmustine, capecitabine, chlorambucil, cytarabine, cyclophosphamide, camptothecin, dacarbazine, dactinomycin, daunorubicin, dexrazoxane, docetaxel, doxorubicin, etoposide, epothilones, floxuridine, fludarabine, fluorouracil, gemcitabine, hydroxyurea, idarubicin, ifosfamide, irinotecan, lomustine, mechlorethamine, mercaptopurine, melphalan, methotrexate, rapamycin (sirolimus), mitomycin, mitotane, mitoxantrone, nitrosurea, paclitaxel, pamidronate, pentostatin, plicamycin, procarbazine, rituximab, streptozocin, teniposide, thioguanine, thiotepa, taxanes, vinblastine, vincristine, vinoreibine, taxol, combretastatins, discodermolides, transpiatinum, 5-fluorouracil radionuclides, and combinations thereof. 5. The pharmaceutical composition of claim 3, wherein the therapeutic agent comprises particles of paclitaxel and wherein more than 50% of the therapeutic agent is in nanoparticle form. 6. The pharmaceutical composition of claim 3, wherein the therapeutic agent is an antibody or antibody fragment which mediates one or more of complement activation, cell mediated cytotoxicity, and opsinization. 7. A method for delivering a therapeutic or diagnostic agent to a disease site in a mammal, wherein the disease is cancer, wherein said method comprises administering to the mammal a therapeutically or diagnostically effective amount of a pharmaceutical composition of claim 1. 8. The method of claim 7, wherein the mammal is a human. 9. The method of claim 7, wherein the disease site is a tumor. 10. The method of claim 9, wherein the tumor is located in the lung, prostate, head, neck, bladder, liver, ovary, kidney, gut, brain, or breast. 11. The method of claim 7, wherein the route of administration is selected from the group consisting of intravenous, subcutaneous, intramuscular, intraperitoneal, intratumoral, oral, and inhalational. 12. The method of claim 7, wherein the diagnostic agent is selected from the group consisting of radioactive agents, MRI contrast agents, X-ray contrast agents, ultrasound contrast agents, and PET contrast agents. 13. The method of claim 7, wherein the therapeutic agent is selected from the group consisting of docetaxel, paclitaxel, taxanes, platinum compounds, antifolates, antimetabolites, antimitotics, DNA damaging agents, proapoptotics, differentiation inducing agents, antiangiogenic agents, antibiotics, hormones, peptides, antibodies, tyrosine kinase inhibitors, kinase inhibitors, anti-vascular endothelial growth factor compounds (anti-VEGFs), anti-epidermal growth factor receptor compounds (anti-EGFRs), tTF, TNF, radionuclides, and combinations thereof. 14. The method of claim 13, wherein the therapeutic agent is selected from the group consisting of genistein, adriamycin, ansamycin, asparaginase, bleomycin, busulphan, cisplatin, carboplatin, carmustine, capecitabine, chlorambucil, cytarabine, cyclophosphamide, camptothecin, dacarbazine, dactinomycin, daunorubicin, dexrazoxane, docetaxel, doxorubicin, etoposide, epothilones, floxuridine, fludarabine, fluorouracil, gemcitabine, hydroxyurea, idarubicin, ifosfamide, irinotecan, lomustine, mechlorethamine, mercaptopurine, melphalan, methotrexate, rapamycin (sirolimus), mitomycin, mitotane, mitoxantrone, nitrosurea, paclitaxel, pamidronate, pentostatin, plicamycin, procarbazine, rituximab, streptozocin, teniposide, thioguanine, thiotepa, taxanes, vinblastine, vincristine, vinorelbine, taxol, combretastatins, discodermolides, transplatinum, 5-fluorouracil, radionuclides, and combinations thereof. 15. The method of claim 13, wherein the therapeutic agent comprises particles of paclitaxel and wherein more than 50% of the therapeutic agent is in nanoparticle form. 16. The method of claim 13, wherein the therapeutic agent is an antibody or antibody fragment which mediates one or more of complement activation, cell mediated cytotoxicity, and opsinization. 17. A kit for diagnosing or treating a disease in a mammal wherein said kit comprises a pharmaceutical composition of claim 1; and instructions for use in the diagnosis and/or treatment of cancer. 18. The method of claim 9, wherein the tumor is selected from oral cavity tumors, pharyngeal tumors, digestive system tumors, the respiratory system tumors, bone tumors, cartilaginous tumors, bone metastases, sarcomas, skin tumors, melanoma, breast tumors, the genital system tumors, urinary tract tumors, orbital tumors, brain and central nervous system tumors, gliomas, endocrine system tumors, thyroid tumors, esophageal tumors, gastric tumors, small intestinal tumors, colonic tumors, rectal tumors, anal tumors, liver tumors, gall bladder tumors, pancreatic tumors, laryngeal tumors, tumors of the lung, bronchial tumors, non-small cell lung carcinoma, small cell lung carcinoma, uterine cervical tumors, uterine corpus tumors, ovarian tumors, vulvar tumors, vaginal tumors, prostate tumors, prostatic carcinoma, testicular tumors, tumors of the penis, urinary bladder tumors, tumors of the kidney, tumors of the renal pelvis, tumors of the ureter, head and neck tumors, parathyroid cancer, Hodgkin's disease, Non-Hodgkin's lymphoma, multiple myeloma, leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia, acute myeloid leukemia, chronic myeloid leukemia, and a combination thereof. 19. The method of claim 9, wherein the tumor is a sarcoma, adenocarcinoma, squamous cell carcinoma, large cell carcinoma, small cell carcinoma, basal cell carcinoma, clear cell carcinoma, oncytoma, or a combination thereof. 20. The method of claim 7, wherein the cancer is colorectal cancer. 21. The method of claim 7, wherein the cancer is breast cancer. 22. The method of claim 7, wherein the cancer is head and neck cancer. 23. The method of claim 7, wherein the cancer is non-small cell lung cancer. 24. The method of claim 7, wherein the cancer is pancreatic cancer. 25. The method of claim 7, wherein the cancer is melanoma. 26. The method of claim 7, wherein the cancer is bladder cancer.

Details for Patent 8,778,302

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2027-03-09
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2027-03-09
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002		2027-03-09